Assets

Autoimmune Assets

Autoimmune diseases rank as the third major category of diseases globally, following cardiovascular diseases and cancer. The global market for autoimmune disease drugs is valued at over $100 billion. Despite a growing emphasis on timely diagnosis and treatment, significant unmet clinical needs persist. The market for new target drugs is projected to expand, with their market share anticipated to increase substantially.

related resource

on this page

  • Why choose Biocytogen's autoimmune disease-related antibody assets?
  • Our autoimmune disease-related projects
  • Selected assets overview

Webinars

View All

    Posters

    View All
      Why choose Biocytogen's autoimmune disease-related antibody assets?
      • Choose from 100+ autoimmune programs generated from our proprietary fully human RenMice platform.
      • Our platform features RenMab™, RenLite®, and RenNano®, suitable for developing monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), bispecific ADCs (bsADCs), and VHHs with high affinity and strong blockade activity.
      • Off-the-shelf therapeutic antibodies are available for multiple indications, including asthma, psoriasis, graft rejection, atopic dermatitis, systemic lupus erythematosus, and rheumatoid arthritis.
      • We offer various collaboration models, including antibody licensing, transfer, and co-development, and have established partnerships with numerous industry leaders. Join us in collaboration to make a global impact on patients with autoimmune diseases!
      Our autoimmune disease-related projects
      Target(s) Format Immune mice Indication Development Stage
      CD40 mAb RenMab Graft rejection Preclinical
      IL4RA mAb RenMab KO Asthma Candidates Selection
      0X40 BpAb RenLite KO Atopic dermatitis Candidates Selection
      ST2 mAb RenMab KO Asthma, Chronic Obstructive Pulmonary Disease (COPD) Candidates Selection
      TNFSF15 (TL1A) mAb RenMab KO Enteritis Candidates Selection
      0X40 mAb RenMab KO Atopic dermatitis Leads Selection
      0X40L mAb RenMab KO, RenLite Atopic dermatitis Leads Selection
      FCER1 mAb RenMab KO Asthma Leads Selection
      IGHE mAb RenMab KO Asthma, Allergy, Allergic rhinitis Leads Selection
      IL23R mAb RenMab KO Psoriasis,Enteritis Leads Selection
      1L2RB mAb RenMab,RenMab KO Vitiligo, Alopecia areata, Graft rejection Leads Selection
      IL36R mAb RenMab KO Psoriasis Leads Selection
      OSM mAb RenMab KO Osteoporosis.Peripheral neuropathy Leads Selection
      OSMR mAb RenMab KO Pruritus, atopic dermatitis, nodular pruritus, inflammatory bowel disease, pulmonary fibrosis,liver fibrosis Leads Selection
      CXCL13 mAb RenMab,RenMab KO Autoimmune disease Leads Selection
      BAFF mAb RenMab KO Systemic lupus erythematosus (SLE), lgA nephropathy, Sjögren's syndrome, rheumatoid arthritis Hits Selection
      CCR9 mAb RenLite KO Inflammatory Bowel Disease Hits Selection
      CD6 mAb RenMab KO Psoriasis Hits Selection
      CD83 mAb RenMab KO Graft versus host disease, inflammatory disease, Transplant rejection Hits Selection
      DC-SIGN mAb RenMab KO Systemic lupus erythematosus Hits Selection
      FCGR2A mAb RenMab KO Asthma Hits Selection
      FCRN mAb RenMab KO Myasthenia gravis,thrombocytopenia Hits Selection
      IFNAR1 mAb RenMab KO Chronic inflammation Hits Selection
      IL13 mAb RenLite Asthma Hits Selection
      IL17RB mAb RenMab KO Psoriasis Hits Selection
      IL25 mAb RenMab KO Asthma Hits Selection
      IL31 mAb RenMab KO Atopic dermatitis Hits Selection
      IL4 mAb RenMab Asthma Hits Selection
      IL5R mAb RenMab KO Asthma Hits Selection
      IL7RA mAb RenMab KO Graft rejection, Allergic disease, Blood tumor Hits Selection
      ITGB7 mAb RenMab KO DSS induces enteritis Hits Selection
      KIT mAb RenMab Hematopoietic stem cell transplantation, Chronic granulomatous disease, AML. GIST Hits Selection
      MADCAM1 mAb RenMab KO Inflammatory Bowel Disease Hits Selection
      MDL-1 mAb RenMab KO Inflammatory bowel Disease Hits Selection
      TSLP mAb RenMab, RenMab KO Asthma, Atopic Dermatitis, chronic Obstructive Pulmonary Diseases (COPD) Hits Selection

      Beyond the projects listed, we have more under development, so stay tuned for updates!

      Selected assets overview

      Contact us today to explore evaluation/licensing/co-development opportunities!

      ST2 mAbs from RenMab KO
      Highlights of our assets:
      • Two groups of clones, each binding to different epitope bins, exhibited high affinity and cross-reactivity between humans and monkeys.
      • Inhibited IL-33 signaling in vitro.